ArticleCell biochemistry and function2026
Therapeutic Efficacy of Metronomic Doxorubicin and Low Dose of Gamma Radiation on Breast Cancer Model.
Article in Cell biochemistry and function, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common malignancy in females internationally. Doxorubicin (DOX) has been well-thought-out as the most effective regimen for breast cancer treatment for several years. The chronic side effects of DOX obligate us to control the dosage that can be used, although its efficacy. Radiotherapy is a vigorous regimen in breast cancer treatment, but correlated side effects are determining factors for a successful recovery. Combined metronomic chemotherapy and radiotherapy, at low doses, can reduce the side effects of single-modality treatments. We have studied the dose 1.8 mg/kg twice per week for 8 weeks of DOX singly or with 0.5 Gy fractionated doses of gamma radiation on inducing cell death, cell cycle arrest, and apoptosis, and also P53, B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X (Bax), and caspase-3 gene expression in an animal breast cancer model. Treatment with DOX resulted in upregulation of apoptosis and downregulation of cell division at an accumulated dose of 0.5 Gy, as well as downregulation of Bcl-2 gene expression and upregulation of p53, Bax, and caspase-3 gene expression in animals bearing breast cancer. In addition, DOX in combination with radiation decreased the tumor size. A metronomic dose of DOX, when used with a low dose of gamma radiation, with the least side effects, could be a successful treatment for breast cancer in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.